Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.

Thomé MP, Borde C, Larsen AK, Henriques JAP, Lenz G, Escargueil AE, Maréchal V.

Antiviral Res. 2019 Dec;172:104615. doi: 10.1016/j.antiviral.2019.104615. Epub 2019 Sep 30.

PMID:
31580916
2.

Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.

Mésange P, Bouygues A, Ferrand N, Sabbah M, Escargueil AE, Savina A, Chibaudel B, Tournigand C, André T, de Gramont A, Larsen AK.

Clin Cancer Res. 2018 Jun 1;24(11):2548-2558. doi: 10.1158/1078-0432.CCR-17-3187. Epub 2018 Feb 28.

3.

Antimicrobial Oligophenalenone Dimers from the Soil Fungus Talaromyces stipitatus.

Zang Y, Genta-Jouve G, Escargueil AE, Larsen AK, Guedon L, Nay B, Prado S.

J Nat Prod. 2016 Dec 23;79(12):2991-2996. doi: 10.1021/acs.jnatprod.6b00458. Epub 2016 Dec 14.

PMID:
27966935
4.

Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.

Escargueil AE, Prado S, Dezaire A, Clairambault J, Larsen AK, Soares DG.

Curr Pharm Des. 2016;22(44):6625-6644. doi: 10.2174/1381612822666160831114002. Review.

PMID:
27587198
5.

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.

Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE.

Oncotarget. 2016 May 3;7(18):25885-901. doi: 10.18632/oncotarget.8292.

6.

Unexpected talaroenamine derivatives and an undescribed polyester from the fungus Talaromyces stipitatus ATCC10500.

Zang Y, Genta-Jouve G, Sun TA, Li X, Didier B, Mann S, Mouray E, Larsen AK, Escargueil AE, Nay B, Prado S.

Phytochemistry. 2015 Nov;119:70-5. doi: 10.1016/j.phytochem.2015.09.002. Epub 2015 Sep 18.

PMID:
26386982
7.

BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.

Rocca CJ, Soares DG, Bouzid H, Henriques JA, Larsen AK, Escargueil AE.

Cell Cycle. 2015;14(13):2080-90. doi: 10.1080/15384101.2015.1042632.

9.

DNA alkylation damage and autophagy induction.

Bordin DL, Lima M, Lenz G, Saffi J, Meira LB, Mésange P, Soares DG, Larsen AK, Escargueil AE, Henriques JA.

Mutat Res. 2013 Oct-Dec;753(2):91-9. doi: 10.1016/j.mrrev.2013.07.001. Epub 2013 Jul 18. Review.

PMID:
23872363
10.

ATP-dependent chromatin remodeling and histone acetyltransferases in 5-FU cytotoxicity in Saccharomyces cerevisiae.

Matuo R, Sousa FG, Bonatto D, Mielniczki-Pereira AA, Saffi J, Soares DG, Escargueil AE, Larsen AK, Henriques JA.

Genet Mol Res. 2013 Apr 26;12(2):1440-56. doi: 10.4238/2013.April.26.6.

11.

Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

Petitprez A, Poindessous V, Ouaret D, Regairaz M, Bastian G, Guérin E, Escargueil AE, Larsen AK.

Int J Oncol. 2013 May;42(5):1644-53. doi: 10.3892/ijo.2013.1868. Epub 2013 Mar 27.

PMID:
23546019
12.

Saccharomyces cerevisiae as a model system to study the response to anticancer agents.

Matuo R, Sousa FG, Soares DG, Bonatto D, Saffi J, Escargueil AE, Larsen AK, Henriques JA.

Cancer Chemother Pharmacol. 2012 Oct;70(4):491-502. Epub 2012 Aug 1. Review.

PMID:
22851206
13.

PARPs and the DNA damage response.

Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JA, Larsen AK, Saffi J.

Carcinogenesis. 2012 Aug;33(8):1433-40. doi: 10.1093/carcin/bgs132. Epub 2012 Mar 19. Review.

PMID:
22431722
14.

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégalophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Fléjou JF, André T, Tournigand C, Chibaudel B, de Gramont A, Larsen AK.

Clin Cancer Res. 2011 Oct 15;17(20):6522-30. doi: 10.1158/1078-0432.CCR-11-1607. Epub 2011 Aug 31.

15.

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.

Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE, Larsen AK.

Mol Cancer Ther. 2011 Aug;10(8):1481-9. doi: 10.1158/1535-7163.MCT-11-0252. Epub 2011 May 27.

16.

Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906.

Soares DG, Battistella A, Rocca CJ, Matuo R, Henriques JA, Larsen AK, Escargueil AE.

Biochem J. 2011 Jul 1;437(1):63-73. doi: 10.1042/BJ20101770.

17.

The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators.

Rocca CJ, Poindessous V, Soares DG, Ouadrani KE, Sarasin A, Guérin E, de Gramont A, Henriques JA, Escargueil AE, Larsen AK.

Biochem Pharmacol. 2010 Aug 1;80(3):335-43. doi: 10.1016/j.bcp.2010.04.012. Epub 2010 Apr 22.

PMID:
20399198
18.

DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP.

Matuo R, Sousa FG, Escargueil AE, Soares DG, Grivicich I, Saffi J, Larsen AK, Henriques JA.

Biochem Pharmacol. 2010 Jan 15;79(2):147-53. doi: 10.1016/j.bcp.2009.08.016. Epub 2009 Aug 25.

PMID:
19712668
19.

5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.

Matuo R, Sousa FG, Escargueil AE, Grivicich I, Garcia-Santos D, Chies JA, Saffi J, Larsen AK, Henriques JA.

J Appl Toxicol. 2009 May;29(4):308-16. doi: 10.1002/jat.1411.

PMID:
19115314
20.

Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells.

Escargueil AE, Poindessous V, Soares DG, Sarasin A, Cook PR, Larsen AK.

J Cell Sci. 2008 Apr 15;121(Pt 8):1275-83. doi: 10.1242/jcs.023259.

21.

What histone code for DNA repair?

Escargueil AE, Soares DG, Salvador M, Larsen AK, Henriques JA.

Mutat Res. 2008 Mar-Apr;658(3):259-70. doi: 10.1016/j.mrrev.2008.01.004. Epub 2008 Jan 20. Review.

PMID:
18296106
22.

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7. Epub 2007 Jul 26.

23.
24.

Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.

Skladanowski A, Côme MG, Sabisz M, Escargueil AE, Larsen AK.

Mol Pharmacol. 2005 Sep;68(3):625-34. Epub 2005 Jun 7.

PMID:
15942022
25.

Molecular cross-talk between the transcription, translation, and nonsense-mediated decay machineries.

Iborra FJ, Escargueil AE, Kwek KY, Akoulitchev A, Cook PR.

J Cell Sci. 2004 Feb 29;117(Pt 6):899-906. Epub 2004 Feb 3.

26.

From DNA damage to G2 arrest: the many roles of topoisomerase II.

Larsen AK, Escargueil AE, Skladanowski A.

Prog Cell Cycle Res. 2003;5:295-300. Review.

PMID:
14593724
27.

Catalytic topoisomerase II inhibitors in cancer therapy.

Larsen AK, Escargueil AE, Skladanowski A.

Pharmacol Ther. 2003 Aug;99(2):167-81. Review.

PMID:
12888111
28.

The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.

Garrigues A, Escargueil AE, Orlowski S.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10347-52. Epub 2002 Jul 26.

29.

Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling.

Escargueil AE, Plisov SY, Skladanowski A, Borgne A, Meijer L, Gorbsky GJ, Larsen AK.

FASEB J. 2001 Oct;15(12):2288-90. Epub 2001 Aug 17.

PMID:
11511510
30.

Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469.

Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK.

J Biol Chem. 2000 Nov 3;275(44):34710-8.

31.

Resistance mechanisms associated with altered intracellular distribution of anticancer agents.

Larsen AK, Escargueil AE, Skladanowski A.

Pharmacol Ther. 2000 Mar;85(3):217-29. Review.

PMID:
10739876
32.

The catalytic activities of DNA topoisomerase II are most closely associated with the DNA cleavage/religation steps.

Scala D, Escargueil AE, Couprie J, Larsen AK.

Biochimie. 1999 Jul;81(7):771-9.

PMID:
10492025

Supplemental Content

Loading ...
Support Center